^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
02/03/2021
Excerpt:
Subsequent therapy for Clear cell histology: Useful in certain circumstances…Sorafenib (category 2B).
